WHO makes new executive board appointments

The World Health Organization (WHO) has made one new and one renewed appointment to its executive board: Zsuzsanna Jakab has been named WHO regional director for Europe, while Dr Luis Gomes Sambo has been re-appointed WHO regional director for Africa. Mrs Jakab, who was previously director of the European Centre for Disease Prevention and Control, succeeds Dr Marc Danzon, who has served as European regional director for the past 10 years. Dr Sambo first took the role as regional director for Africa in 2005; before that he held a number of health-based roles in Angola, including vice-minister of health, director of health service in the Cabinda province and director of international co-operation at the ministry of health in Luanda.

The World Health Organization (WHO) has made one new and one renewed appointment to its executive board: Zsuzsanna Jakab has been named WHO regional director for Europe, while Dr Luis Gomes Sambo has been re-appointed WHO regional director for Africa. Mrs Jakab, who was previously director of the European Centre for Disease Prevention and Control, succeeds Dr Marc Danzon, who has served as European regional director for the past 10 years. Dr Sambo first took the role as regional director for Africa in 2005; before that he held a number of health-based roles in Angola, including vice-minister of health, director of health service in the Cabinda province and director of international co-operation at the ministry of health in Luanda.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Skyhawk Flies High With Another Big Pharma, Getting Up To $2bn In Merck KGaA Deal

 
• By 

Deal Snapshot: Skyhawk raised its first seed funding in 2018 and has funded its operations primarily through partnering fees to date, including its latest agreement with Merck KGaA.

Wegovy’s Win In MASH Gives Novo A Much-Needed Edge Over Lilly

 
• By 

Just days after discontinuing a Phase III trial for a separate MASH compound, Novo Nordisk has secured the US FDA’s accelerated approval for Wegovy to treat the fatty liver disease.

Leo Keeps On Profitable Path With Solid H1 Sales Growth

 
• By 

The Danish firm's atopic dermatitis drug Adbry is performing well despite strong competition from Sanofi/Regeneron’s Dupixent.

Indegene Exec On DTP Distribution As A ‘Tactical Solution’, Feasibility Of MFN Model

 

Senior Indegene executive William Lobb talks about complexities of the direct-to-patient distribution model in the US and underlines that it isn’t a comprehensive healthcare fix. The feasibility of MFN pricing and why it may be “catastrophic” to the industry were some of the other topics discussed.

More from Scrip

Pipeline Watch: Seven Approvals And Five Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Indegene Exec On DTP Distribution As A ‘Tactical Solution’, Feasibility Of MFN Model

 

Senior Indegene executive William Lobb talks about complexities of the direct-to-patient distribution model in the US and underlines that it isn’t a comprehensive healthcare fix. The feasibility of MFN pricing and why it may be “catastrophic” to the industry were some of the other topics discussed.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: a look at the likely top drugs in 2030; Lilly CEO advocates US/Europe pricing rebalance; Insmed sees $5bn-plus market for Brinsupri; royalty deals go mainstream; Phase III win sets stage for Epkinly label expansion.